Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type Clinical Trial

Official title:

A Multicentre, Open-label, Single-arm, Phase I/II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04509466
• Other study ID #: HE071-CSP-012
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 15, 2020
• Est. completion date: January 30, 2022

Study information

• Verified date: August 2020
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal natural killer/T-cell lymphoma, nasal type (NKTCL).

Description:

This is a multicentre, open-label, single-arm, phase I/II clinical study with a dose-escalation stage (part 1) and a dose-expansion stage (part 2). In part 1, patients with treatment-naïve, relapsed/refractory extranodal natural killer/T-cell lymphoma (nasal type) will be assigned to receive sequentially higher doses of liposomal mitoxantrone hydrochloride plus a standard dose of pegaspargase every 21 days (a cycle). The dose escalation initially will follow an accelerated titration design for the first two dosing groups, then follow a classic 3+3 design. All dose-escalation decisions will be based on the safety data generated from the currently highest dose group. The maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of liposomal mitoxantrone hydrochloride will be determined in part 1. In part 2, additional patients will be recruited into two groups,the treatment-naïve group and the relapsed or refractory group, to receive liposomal mitoxantrone hydrochloride at the RP2D combined with a standard dose of pegaspargase. All patients will receive the treatment until disease progression, or observation of unacceptable grade 3 drug-related adverse events (a maximum of 6 cycles).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 41
• Est. completion date: January 30, 2022
• Est. primary completion date: January 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign informed consent;

2. Age =18, =75 years, no gender limitation;

3. Histologically confirmed diagnosis of treatment-naïve, relapsed or refractory extranodal NK/T-cell lymphoma nasal type (NKTCL);

4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

5. At least one measurable lesion as per Lugano 2014 criteria;

6. Adequate bone marrow, liver, renal and coagulation function

Exclusion Criteria:

1. Known central nervous system involvement caused by lymphoma;

2. Known infiltration of the bone marrow according to criteria for leukemia (=20% myeloblast in the blood or bone marrow);

3. Known hemophagocytic syndrome;

4. History of allergy and contraindications to mitoxantrone hydrochloride and/or asparaginase/ pegaspargase;

5. Chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatment within 4 weeks of the first dose of the study drug (2 weeks for the local radiation therapy for pain relief);

6. Life expectancy < 3 months

7. Impaired cardiac function or serious cardiac disease;

8. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection;

9. Acute symptomatic or chronic pancreatitis within 4 weeks prior to screening;

10. History of, or known additional tumor (exception: non-melanoma skin cancer (in situ) and cervical cancer (in situ) which have been cured and have not recurred within 5 years);

11. History of solid organ transplantation, autologous hematopoietic stem cell transplantation within 6 months prior to screening, or allogeneic hematopoietic stem cell transplantation before screening;

12. Major surgery within 4 weeks prior to screening. Or have a surgical schedule during the study period;

13. A serious infection within 4 weeks prior to screening and not suitable for the study according to the judgment of the investigator;

14. Uncontrolled diabetes at screening;

15. Known alcohol or drug abuse;

16. Known psychiatric disorders or cognitive disorder;

17. 17. Pregnant or breastfeeding women, or patients who are expecting to conceive or father in 12 months (starting with the screening visit);

18. Not suitable for this study as determined by the investigator due to other reasons.

Related Conditions & MeSH terms

• Extranodal NK/T-cell Lymphoma, Nasal Type
• Lymphoma, Extranodal NK-T-Cell

Intervention

Drug:
• Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase
Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle. Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.
• Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle. Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.
• Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle. Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.

Locations

Country	Name	City	State
China	the Affiliated Cancer Hospital of Guizhou Medical University	Guiyang	Guizhou

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1:dose limiting toxicities (DLTs)	The incidence and severity of adverse events (AEs), abnormalities in clinical laboratory assessments, ECGs, vital sign assessments, and physical exams	Cycle 1 (a cycle = 21 days)
Primary	Part 2 (treatment-naïve patients):The percentage of patients who achieve complete response (CR)	CR rates at the end of chemotherapy	up to 18 weeks
Primary	Part 2 (relapsed or refractory patients):The percentage of patients who achieve complete response (CR)	CR rates at the end of treatment(including chemotherapy and radiation)	up to 26 weeks
Primary	Part 2 (relapsed or refractory patients):The percentage of patients who achieve partial response (PR)	PR rates at the end of treatment(including chemotherapy and radiation)	up to 26 weeks
Secondary	Part 1 the preliminary antitumor efficacy: complete response rate (CR)	the percentage of patients who achieve complete response (CR)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks
Secondary	Part 1 the preliminary antitumor efficacy:overall response rate (ORR)	the percentage of patients who achieve complete response (CR)and partial response (PR)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks
Secondary	Part 1 the preliminary antitumor efficacy:disease control rate (DCR)	the percentage of patients who achieve complete response (CR)?partial response (PR) and stable disease(SD)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks
Secondary	Part 1: The pharmacokinetic parameters Cmax	maximum concentration(Cmax)	At the end of Cycle 1 and Cycle 3 (each cycle is 21 days)
Secondary	Part 1: The pharmacokinetic parameters AUC0-t	area under the curve from zero to the time point(AUC0-t)	At the end of Cycle 1 and Cycle 3 (each cycle is 21 days)
Secondary	Part 2 (treatment-naïve patients):The preliminary antitumor efficacy complete response rate (CR)	the percentage of patients who achieve complete response (CR)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks
Secondary	Part 2 (treatment-naïve patients):The preliminary antitumor efficacy overall response rate (ORR)	the percentage of patients who achieve complete response (CR)and partial response (PR)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks
Secondary	Part 2 (treatment-naïve patients):The preliminary antitumor efficacy disease control rate (DCR)	the percentage of patients who achieve complete response (CR)?partial response (PR) and stable disease(SD)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks
Secondary	Part 2 (treatment-naïve patients):The preliminary safety index	The incidence and severity of adverse events (AEs), abnormalities in clinical laboratory assessments, ECGs, vital sign assessments, and physical exams	through study completion, an average of 1 year
Secondary	Part 2 (relapsed or refractory patients): The preliminary antitumor efficacy	disease control rate (DCR):the percentage of patients who achieve complete response (CR)?partial response (PR) and stable disease(SD)(including at the end of chemotherapy and at the end of treatment)	up to 26 weeks